FDA Approves Yeztugo for HIV PrEP Lasting 6 Months

The FDA approved lenacapavir, an injectable HIV-1 capsid inhibitor, to be used as PrEP to reduce the risk of ...

JUNE 18, 2025

Biktarvy Effective in Those With Adherence Challenges

BIC/FTC/TAF was effective in suppressing HIV viral load, even among adults who had adherence challenges

NOVEMBER 29, 2023

FDA Grants New Indication for Veklury to Treat COVID-19 in People With Hepatic Impairment

The FDA granted a supplemental new drug application for the use of remdesivir with no dose adjustments to treat ...

AUGUST 25, 2023

Gilead Subsidiary to Launch Generic HCV Drugs

The list price of authorized generics to reflect discounts in the system today.

SEPTEMBER 26, 2018

FDA Expands Indication for Truvada for PrEP Among Adolescents

The FDA granted a new indication for Gilead's Truvada to reduce the risk for sexually acquired HIV-1 in at-risk ...

MAY 15, 2018

Switching HIV Regimen Found Safe

Switching to the newly approved Biktarvy in virologically suppressed adults maintained viral suppression with fewer ...

MARCH 7, 2018

ViiV Files Suit Against Gilead Over HIV Drug Patents

ViiV claims bictegravir infringes on its patent covering dolutegravir and many other compounds that include ...

FEBRUARY 8, 2018

FDA Approves Biktarvy Triple Therapy for HIV Infection

The FDA approved Gilead's Biktarvy, a once-daily, single-tablet regimen for the treatment of HIV-1 infection.

FEBRUARY 8, 2018

HIV Drugs in the Pipeline: Expected Approvals for 2018

Pharmaceutical companies are looking at antiretroviral therapy regimens that are easier on patients with HIV.

DECEMBER 29, 2017

ViiV Healthcare Announces Phase 3 Study of Cabotegravir for PrEP in Women

ViiV Healthcare announced the start of a new phase 3 trial looking at cabotegravir for use as PrEP in women.

DECEMBER 1, 2017

Bictegravir-Containing Compound Found Noninferior in Phase 3 Trial

Bictegravir is a novel, potent integrase strand transfer inhibitor (INSTI), which features a high in vitro barrier ...

OCTOBER 10, 2017

FDA Approves Vosevi for Patients With Chronic HCV

The FDA has approved Vosevi, a single-tablet pangenotypic regimen for the treatment chronic HCV infection in adults ...

JULY 19, 2017